Literature DB >> 19770273

Phenylbutyrate induces antimicrobial peptide expression.

Jonas Steinmann1, Skarphédinn Halldórsson, Birgitta Agerberth, Gudmundur H Gudmundsson.   

Abstract

Antimicrobial peptides (AMPs) are important components of our first line of defense. Induction of AMPs such as LL-37 of the cathelicidin family might provide a novel approach in treating bacterial infections. In this study we identified 4-phenylbutyrate (PBA) as a novel inducer of AMP expression and investigated affected regulatory pathways. We treated various cell lines with PBA and assessed mRNA expression by real-time reverse transcriptase PCR (RT-PCR). Cathelicidin AMP (CAMP) gene expression was found to be upregulated in all four cell lines tested. Additionally, we found that the beta-defensin 1 gene was upregulated in the lung epithelial cell line VA10 while being downregulated in the monocytic cell line U937. Further we found that PBA induced CAMP gene expression synergistically with 1,25-dihydroxyvitamin D(3) at both protein and mRNA levels. The general mechanism of induction of CAMP gene expression by PBA was found to be dependent on protein synthesis. Results from quantitative chromatin immunoprecipitation experiments challenge the common view that histone deacetylase inhibitors directly increase CAMP gene expression. Furthermore, we have demonstrated that inhibition of the mitogen-activated protein kinases MEK1/2 and c-Jun N-terminal kinase attenuate PBA-induced CAMP gene expression. Similarly, alpha-methylhydrocinnamate (ST7), an analogue of PBA, increases CAMP gene expression. Our findings contribute to understanding of the regulation of AMP expression and suggest that PBA and/or ST7 is a promising drug candidate for treatment of microbial infections by strengthening the epithelial antimicrobial barriers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19770273      PMCID: PMC2786349          DOI: 10.1128/AAC.00818-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

Review 1.  Acetylation and deacetylation of non-histone proteins.

Authors:  Michele A Glozak; Nilanjan Sengupta; Xiaohong Zhang; Edward Seto
Journal:  Gene       Date:  2005-11-11       Impact factor: 3.688

2.  Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.

Authors:  Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin
Journal:  Science       Date:  2006-02-23       Impact factor: 47.728

3.  Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils.

Authors:  O Chertov; D F Michiel; L Xu; J M Wang; K Tani; W J Murphy; D L Longo; D D Taub; J J Oppenheim
Journal:  J Biol Chem       Date:  1996-02-09       Impact factor: 5.157

4.  Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3.

Authors:  Adrian F Gombart; Niels Borregaard; H Phillip Koeffler
Journal:  FASEB J       Date:  2005-07       Impact factor: 5.191

5.  Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.

Authors:  E Fibach; P Prasanna; G P Rodgers; D Samid
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

6.  Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein.

Authors:  J W Larrick; M Hirata; R F Balint; J Lee; J Zhong; S C Wright
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

7.  In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.

Authors:  R C Rubenstein; M E Egan; P L Zeitlin
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

8.  Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy.

Authors:  S Kemp; H M Wei; J F Lu; L T Braiterman; M C McGuinness; A B Moser; P A Watkins; K D Smith
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

9.  The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes.

Authors:  G H Gudmundsson; B Agerberth; J Odeberg; T Bergman; B Olsson; R Salcedo
Journal:  Eur J Biochem       Date:  1996-06-01

10.  PU.1 and bacterial metabolites regulate the human gene CAMP encoding antimicrobial peptide LL-37 in colon epithelial cells.

Authors:  Stefan Termén; Maria Tollin; Eduardo Rodriguez; Sigrún H Sveinsdóttir; Bjarki Jóhannesson; Andreas Cederlund; Jan Sjövall; Birgitta Agerberth; Gudmundur H Gudmundsson
Journal:  Mol Immunol       Date:  2008-07-26       Impact factor: 4.407

View more
  58 in total

Review 1.  Potential beneficial effects of butyrate in intestinal and extraintestinal diseases.

Authors:  Roberto Berni Canani; Margherita Di Costanzo; Ludovica Leone; Monica Pedata; Rosaria Meli; Antonio Calignano
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

2.  Treatment with Entinostat Heals Experimental Cholera by Affecting Physical and Chemical Barrier Functions of Intestinal Epithelia.

Authors:  Protim Sarker; Atanu Banik; Roger Stromberg; Gudmundur H Gudmundsson; Rubhana Raqib; Birgitta Agerberth
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 3.  Inflammatory bowel disease: an impaired barrier disease.

Authors:  Simon Jäger; Eduard F Stange; Jan Wehkamp
Journal:  Langenbecks Arch Surg       Date:  2012-11-18       Impact factor: 3.445

Review 4.  Influences of the Gut Microbiota on DNA Methylation and Histone Modification.

Authors:  Jianzhong Ye; Wenrui Wu; Yating Li; Lanjuan Li
Journal:  Dig Dis Sci       Date:  2017-03-24       Impact factor: 3.199

5.  Nanofiber-based sutures induce endogenous antimicrobial peptide.

Authors:  Shixuan Chen; Liangpeng Ge; Adrian F Gombart; Franklin D Shuler; Mark A Carlson; Debra A Reilly; Jingwei Xie
Journal:  Nanomedicine (Lond)       Date:  2017-09-29       Impact factor: 5.307

Review 6.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

7.  Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37.

Authors:  Ylva Kai-Larsen; Petra Lüthje; Milan Chromek; Verena Peters; Xiaoda Wang; Asa Holm; Lavinia Kádas; Kjell-Olof Hedlund; Jan Johansson; Matthew R Chapman; Stefan H Jacobson; Ute Römling; Birgitta Agerberth; Annelie Brauner
Journal:  PLoS Pathog       Date:  2010-07-22       Impact factor: 6.823

8.  Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages.

Authors:  Rokeya Sultana Rekha; S S V Jagadeeswara Rao Muvva; Min Wan; Rubhana Raqib; Peter Bergman; Susanna Brighenti; Gudmundur H Gudmundsson; Birgitta Agerberth
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

9.  Innate Effector Systems in Primary Human Macrophages Sensitize Multidrug-Resistant Klebsiella pneumoniae to Antibiotics.

Authors:  Rokeya Sultana Rekha; Harpa Karadottir; Sultan Ahmed; Gudmundur H Gudmundsson; Birgitta Agerberth; Peter Bergman
Journal:  Infect Immun       Date:  2020-07-21       Impact factor: 3.441

10.  Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia.

Authors:  A Bekele; N Gebreselassie; S Ashenafi; E Kassa; G Aseffa; W Amogne; M Getachew; A Aseffa; A Worku; R Raqib; B Agerberth; U Hammar; P Bergman; G Aderaye; J Andersson; S Brighenti
Journal:  J Intern Med       Date:  2018-05-23       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.